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Background/Purpose: Peutz–Jeghers syndrome (PJS) is an autosomal dominant inherited disorder that is
characterized by intestinal hamartomatous polyps and mucocutaneous pigmentation. Recently, germline
mutations in the LKB1 gene have been reported to underlie PJS. The gene that encodes this serine/threonine
kinase is located at chromosome 19p13.3. The aim of this study was to investigate the clinical and genetic
characteristics of PJS patients in Taiwan.
Methods: We searched the patient database of the National Taiwan University Hospital, a tertiary medical
center in Taiwan, between January 1990 and November 2005. Patients’ clinical information, demographic
data, endoscopic pictures, and outcome were reviewed and analyzed. After obtaining informed consent,
DNA and RNA were extracted from peripheral blood mononuclear cells and the LKB1 gene was sequenced.
Results: A total of 14 unrelated patients who fulfilled the diagnostic criteria of PJS were included, and
seven of them had genetic analysis performed. Mucocutaneous pigmentation was the most frequent pres-
entation. Hamartomas occur most commonly in the small intestine (86%). Frequent abdominal compli-
cations include intussusception and gastrointestinal bleeding. Four germline mutations were found
(57.1%). Three resulted in stop codons at codon 60, 162 (novel mutation), and 308. The fourth mutation
was a missense mutation at codon 239 (novel mutation).
Conclusion: Compared with other countries, PJS patients in Taiwan tended to have more extensive polyps
in the gastrointestinal tract, with intussusception being the most common abdominal symptom.
Mutations in the LKB1 gene were identified in 57% of the probands in Taiwan.
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Peutz–Jeghers syndrome (PJS) is an autosomal
dominant disorder that is characterized by multi-
ple hamartomatous polyps of the gastrointestinal
(GI) tract and by mucocutaneous pigmentation.
Approximately 1/120,000 people have PJS.1 PJS
was first identified by the Dutch physician Peutz
in 1921, and the original family was described 
by Jeghers in 1949.2 These patients often present
in the first decade of life with pigmentation or
complications of small bowel polyps, such as ob-
struction or intussusception. In addition to these
typical symptoms, patients often have an increased
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risk of epithelial malignancy, particularly of the GI
tract. Other sites include the pancreas, breast, lung,
testes and ovaries (so-called sex cord tumors with
annular tubules). The overall incidence of cancer
among PJS patients has been estimated to be 15-
fold higher than that in the general population.3
The predisposing gene for PJS has recently
been identified as LKB1. This gene maps to chro-
mosome sub-band 19p13.3 by linkage analysis,
comparative genomic hybridization, and loss of
heterozygosity analysis.4 The gene is predicted to
encode a serine/threonine kinase and has also
been referred to as serine/threonine kinase 11
(STK11). Human LKB1 consists of nine coding
exons with a 433-amino acid coding sequence and
one non-coding exon 10. Codons 50–337 encode
the catalytic kinase domain. Truncating germline
mutations in LKB1 have been reported in PJS pa-
tients.4,5 Moreover, PJS polyps have typically
shown loss of heterozygosity that results in bial-
lelic loss of LKB1 function.4 Therefore, it has been
suggested that LKB1 acts as a tumor suppressor
in hamartomatous polyps and other neoplasms
of PJS patients.4
In this study, we report the clinical characteris-
tics of 14 unrelated PJS patients in Taiwan, as well
as the genetic analyses of seven of these patients.
Materials and Methods
Patients
Fourteen patients who were diagnosed with PJS
from January 1990 to November 2005 in the
National Taiwan University Hospital (a tertiary
medical center in Taiwan) were retrospectively
reviewed and analyzed. The diagnostic criteria
for PJS in this study were as follows: (1) three 
or more histologically confirmed Peutz–Jeghers
polyps; (2) any number of Peutz–Jeghers polyps
with a family history of PJS; (3) characteristic,
prominent, mucocutaneous pigmentation with 
a family history of PJS; and (4) any number of
Peutz–Jeghers polyps and characteristic, promi-
nent, mucocutaneous pigmentation.6 After signing
the informed consent document for participation
in our study, which was approved (9000017996)
by the Institutional Review Board of the Ethics
Committee of the National Taiwan University
Hospital, DNA and RNA were extracted from
whole venous blood. To clarify further the iden-
tified changes as a polymorphism or mutation,
population analysis with genomic DNA from
200 anonymous individuals from the DNA bank
of the Department of Medical Genetics of the
National Taiwan University Hospital was used as
the population control.
DNA and RNA purification
Genomic DNA was purified from whole blood by
using the Genomic DNA Mini Kit (Geneaid, 
Tao-Yuan, Taiwan) according to the manufacturer’s
instructions. Lymphocytes were isolated from
whole blood by using the Ficoll-Paque Plus system
(Amersham Pharmacia Biotech, Uppsala, Sweden).
Total RNA was isolated using the RNeasy kit
(Qiagen, Hilden, Germany), following the manu-
facturer’s instructions.
Polymerase chain reaction (PCR)
PCRs of LKB1 exons were performed in a 50-μL
reaction that contained 10 mmol/L Tris–HCl, 
pH 8.3, 50 mmol/L KCl, 1.5–4.5 mmol/L MgCl2,
50 mmol/L dNTPs, 0.25 mmol/L of each primer,
100 ng genomic DNA, and 1 U Bio-ThermStar
DNA polymerase (Gene Craft GmbH, Münster,
Germany). The PCR reaction was initiated with a
10-minute denaturation step at 95°C to activate
Bio-ThermStar DNA polymerase. Subsequent de-
naturing steps included 94°C for 20 seconds and
an extension step of 72°C for 45 seconds. Primer
pairs and the adjusted temperatures for individ-
ual amplicons are given in Table 1.
Reverse-transcriptase PCR (RT-PCR)
Standard random priming methods with Moloney
murine leukemia virus RT (Promega, Madison, WI,
USA) and RNAse inhibitor (Promega) were used
to obtain 20 μL cDNA. RT-PCR was performed in
Gene Amp PCR System 2400 (PE Applied Biosys-
tems, Foster City, CA, USA) under the following
conditions: 3 μL cDNA, 1 × buffer (with MgCl2),
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250 μM dNTPs, 0.8 μM reverse and forward prim-
ers, 2 U Amplitaq Gold polymerase (PE Applied
Biosystems) and water, in a final volume of 50 μL.
The RT-PCR products obtained with the primer
sets are also listed in Table 1.
Direct sequencing
Sequencing reactions were performed for the PCR
products of the LKB1 gene using the ABI PRISM
Dye Terminator Cycle Sequencing Ready Reaction
kit (PE Applied Biosystems). Electrophoresis was
carried out using a Genetic Analyzer 310 (PE Ap-
plied Biosystems) equipped with long-read se-
quencing capillary and POP-6 sequencing polymer
(PE Applied Biosystems). Primers used for direct
sequencing reactions were the same as for the
PCRs (Table 1).
Results
Clinical features
The clinical phenotypes of the 14 unrelated PJS
patients are summarized in Table 2. There were
four male and 10 female patients, and symptoms
appeared at a median age of 19 years. The mean
age at diagnosis was 18.9 years (range, 2–72
years). Family history was positive in six cases
(42.9%). All these patients presented with numer-
ous pigmented spots on the lips and the buccal
mucosa as the extra-GI tract manifestation. They
were also characterized by the presence of multiple
GI hamartomatous polyps (93%). Hamartomas
occurred most commonly in the small intestine
(86%), but also in the stomach (79%), and
colon (71%).
Table 1. Primers and conditions used for LKB1 gene analysis
LKB1 gene Sequence Tm (°C) Product size (bp)
genomic DNA
Exon 1 forward 5-CGG ACT CAG GGC TGG CGG CG-3 62 385
reverse 5-CAG CAC CGT GAC TGG CCC GGC-3
Exon 2 forward 5-CGT TGG GTC GGC TGA TAC-3 60 164
reverse 5-TCC CAC GGA GGC CCC GCG G-3
Exon 3 forward 5-GGC CTG TGA GTG GGG CCG-3 66 201
reverse 5-GGA GCC TGC CCT GCC TGG, CC-3
Exon 4–5 forward 5-AGG GAG GCC TCG GCC CCA G-3 66 426
reverse 5-GTG TGC GTG TGG TGA GTG C-3
Exon 6 forward 5-CTT GAC TGA CCA CGC CTT TC-3 60 248
reverse 5-ACC TGA CAC CCC CAA CCC TAC-3
Exon 7 forward 5-TGC CCA GCT GAC AGG CTC C-3 64 136
reverse 5-TCC CTG CAG CCT CGG CCC CAC-3
Exon 8 forward 5-ACT GGA CCG CCC TGG TGC CAG-3 66 295
reverse 5-GGA CAT CCT GGC CGA GTC AGC-3
Exon 9 forward 5-GCG CCC CTC AGC TCA GGC CAC-3 64 349
reverse 5-CGG TCA CCA TGA CTG ACT AGC-3
cDNA
Exon 1 forward 5-GAG AAG GGA AGT CGG AAC A-3 60 1101
reverse 5-CGG CAC CAC AGT CAT GC-3
Exon 2 forward 5-CGG GTA CTT CTG TCA GCT G-3 62 906
reverse 5-GAA GAC TGA GGG CCT GG-3
Peutz–Jeghers syndrome in Taiwan
J Formos Med Assoc | 2010 • Vol 109 • No 5 357
Ta
b
le
 2
.
Cl
in
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 P
eu
tz
–J
eg
he
rs
 p
at
ie
nt
s
Ca
se
A
ge
 
A
ge
 a
t 
Pi
gm
en
ta
tio
n
Fa
m
ili
al
 
LK
B1
Po
ly
p 
lo
ca
tio
n
Cl
in
ic
al
 h
is
to
ry
(y
r)
/s
ex
di
ag
no
si
s 
(y
r)
m
ut
at
io
n
1
14
/F
12
Ye
s
N
o
Ye
s
St
om
ac
h,
 il
eu
m
, r
ec
tu
m
 
La
pa
ro
to
m
y,
 m
an
ua
l r
ed
uc
tio
n 
an
d 
po
ly
p 
re
se
ct
io
n,
 
12
-y
r-
ol
d,
 in
tu
ss
us
ce
pt
io
n,
 3
 il
ea
l p
ol
yp
2
18
/F
11
Ye
s
N
o
Ye
s
St
om
ac
h,
 d
uo
de
nu
m
, 
Je
ju
nu
m
 re
se
ct
io
n 
at
 1
4 
yr
 o
f a
ge
, i
nt
us
su
sc
ep
tio
n,
 1
 je
ju
nu
m
 p
ol
yp
je
ju
nu
m
, r
ec
tu
m
3
10
/F
2
Ye
s
N
o
–
St
om
ac
h,
 je
ju
nu
m
, 
D
-c
ol
on
 re
du
ct
io
n 
an
d 
su
rg
ic
al
 p
ol
yp
ec
to
m
y,
 7
-y
r-
ol
d,
 
D
-c
ol
on
in
tu
ss
us
ce
pt
io
n,
 1
 D
-c
ol
on
 p
ol
yp
4
22
/F
13
Ye
s
Ye
s
N
o
St
om
ac
h,
 d
uo
de
nu
m
, 
M
an
ua
l r
ed
uc
tio
n 
an
d 
se
gm
en
ta
l r
es
ec
tio
n 
of
 te
rm
in
al
 il
eu
m
. 
je
ju
nu
m
, i
le
um
, A
-c
ol
on
Tw
o 
je
ju
nu
m
–j
ej
un
um
 in
tu
ss
us
ce
pt
io
n 
an
d 
ile
um
–T
-c
ol
on
 
in
tu
ss
us
ce
pt
io
n,
 1
6-
yr
-o
ld
, s
ev
er
al
 je
ju
nu
m
 a
nd
 il
eu
m
 p
ol
yp
s
O
pe
n 
re
du
ct
io
n
+
se
gm
en
ta
l i
le
um
 re
se
ct
io
n,
 il
ea
l–
ile
al
 in
tu
ss
us
ce
pt
io
n,
 
21
-y
r-
ol
d,
 m
ul
tip
le
 il
eu
m
 p
ol
yp
s
5
19
/F
15
Ye
s
N
o
Ye
s
St
om
ac
h,
 d
uo
de
nu
m
, 
En
te
ro
to
m
y 
at
 1
7 
yr
 o
f a
ge
, d
uo
de
na
l p
ol
yp
s
si
gm
oi
d 
co
lo
n
6
10
/F
8
Ye
s
Ye
s
–
Je
ju
nu
m
N
ot
 re
m
ar
ka
bl
e
7
58
/F
36
Ye
s
N
o
N
o
St
om
ac
h,
 d
uo
de
nu
m
, 
Sp
on
ta
ne
ou
s 
re
du
ct
io
n 
at
 5
7 
yr
 o
f a
ge
, i
nt
us
su
sc
ep
tio
n,
 d
uo
de
nu
m
 
je
ju
nu
m
, S
ig
m
oi
d 
co
lo
n
an
d 
je
ju
nu
m
 p
ol
yp
s 
s/
p 
en
do
sc
op
ic
 p
ol
yp
ec
to
m
y
8
10
/M
3
Ye
s
N
o
N
o
Ce
cu
m
, r
ec
tu
m
N
ot
 re
m
ar
ka
bl
e
9
26
/F
22
Ye
s
Ye
s
–
St
om
ac
h,
 d
uo
de
nu
m
, 
Sm
al
l b
ow
el
 re
se
ct
io
n 
at
 2
2 
yr
 o
f a
ge
, i
nt
us
su
sc
ep
tio
n,
 
co
lo
n
je
ju
nu
m
 p
ol
yp
s
10
42
/F
16
Ye
s
Ye
s
–
St
om
ac
h,
 d
uo
de
nu
m
, 
Sp
on
ta
ne
ou
s 
re
du
ct
io
n 
at
 3
5 
yr
 o
f a
ge
, i
nt
us
su
sc
ep
tio
n,
 d
uo
de
nu
m
 
re
ct
um
po
ly
ps
 s
/p
 e
nd
os
co
pi
c 
re
se
ct
io
n
11
42
/M
28
Ye
s
Ye
s
Ye
s
St
om
ac
h,
 d
uo
de
nu
m
, 
Sm
al
l b
ow
el
 re
se
ct
io
n 
at
 2
8 
yr
 o
f a
ge
, i
nt
us
su
sc
ep
tio
n,
 je
ju
nu
m
 p
ol
yp
s.
je
ju
nu
m
, c
ol
on
Ri
gh
t h
em
ic
ol
ec
to
m
y 
at
 3
8 
yr
 o
f a
ge
, c
ol
on
 c
an
ce
r, 
co
lo
n 
po
ly
ps
12
74
/M
72
Ye
s
N
o
–
St
om
ac
h 
1.
 E
nt
er
ot
om
y 
at
 7
3 
yr
 o
f a
ge
, 1
 g
as
tr
ic
 c
ar
di
a 
po
ly
p
2.
 L
un
g 
ca
nc
er
13
23
/M
12
Ye
s
N
o
–
St
om
ac
h,
 d
uo
de
nu
m
, 
Re
du
ct
io
n 
an
d 
en
te
ro
to
m
y 
at
 1
2 
yr
 o
f a
ge
, i
nt
us
su
sc
ep
tio
n,
 
je
ju
nu
m
, i
le
um
4 
st
om
ac
h 
po
ly
ps
, 1
 d
uo
de
na
l p
ol
yp
, 1
8 
je
ju
na
l a
nd
 il
ea
l p
ol
yp
s
14
26
/F
14
Ye
s
Ye
s
–
Je
ju
nu
m
 
En
te
ro
to
m
y 
at
 1
4 
yr
 o
f a
ge
, 1
 je
ju
na
l p
ol
yp
M
=
M
al
e;
 F
=
fe
m
al
e;
 –
=
no
t t
es
te
d;
 D
-c
ol
on
=
de
sc
en
di
ng
 c
ol
on
; A
-c
ol
on
=
as
ce
nd
in
g 
co
lo
n;
 T
-c
ol
on
=
tr
an
sv
er
se
 c
ol
on
.
M.T. Weng, et al
358 J Formos Med Assoc | 2010 • Vol 109 • No 5
The most frequent complication in these pa-
tients was anemia (78.6%), followed by polyp-
related intussusception (64.3%). Seven of the
nine patients with polyps (77.8%) received sur-
gery for intussusception, and the others received
conservative treatment. Three patients suffered
from episodes of profound GI bleeding; two sub-
sided after endoscopic treatment and the third
required surgical intervention. One patient devel-
oped Dukes’ classification B1 colon cancer. Sub-
total colectomy was performed and no evidence
of recurrence was noted after a 5-year follow-up.
Another patient had lung cancer with bone metas-
tasis and was later lost to follow-up. No mortality
was noted in these patients from the chart record
(Table 3).
Genetic analysis
Mutations were detected in four of the seven
probands (57%) subjected to genetic analysis 
of the LKB1 gene from genomic DNA. The direct
sequencing results are displayed in Figure 1 and
summarized in Table 4. Among the four mutations,
two nonsense mutations, one frameshift and one
missense mutation were identified. Case 2 was a
guanine to adenine substitution at base 923 that
resulted in a change from tryptophan to a prema-
ture stop signal at codon 308 in exon 8. Case 5 was
an insertion of cytosine at base 117 that created a
frameshift mutation that resulted in a premature
stop signal at codon 162. Case 11 was a thymine to
guanine substitution at base 180 that resulted in a
premature stop signal at codon 60 [TAC (Tyr) to
TAG (stop)]. Case 1 was a missense mutation with
a thymine to guanine substitution at base 715 that
resulted in a tryptophan to glycine change at co-
don 239 in exon 5. This missense change was not
detected in the 200 control DNA samples.
All four mutations were identified by PCR from
genomic DNA. Only one mutation was detected
by RT-PCR based on cDNA. The RT-PCR product
of case 5 was displayed as two fragments of 569
and 1101 bp (Figure 2). The size of the smaller frag-
ment was compatible with the premature stop
product, which did not appear in the control sam-
ples. However, no premature stop products were
found in the RT-PCR analysis of cases 2 and 11.
This may be explained by the rapid destruction
of the mutated transcripts, which is known as
nonsense-mediated mRNA decay.
Discussion
Although PJS is not a common disease, patients
usually have major medical/surgical issues (such
as intussusception or GI bleeding) in early life and
a higher risk of cancer in later life. It is important
Table 4. Germline mutation identified in the LKB1 gene
Case LKB1 change Exon Bases Codons Amino acid change
1 TGG  TGG + GGG 5 715 239 W  G (unknown significance)
2 TGG  TGG + TAG 8 923 308 W  stop codon
4 –
5 Insert C 1 117 39 Stop at codon 162
7 –
8 –
11 TAC  TAC + TAG 1 180 60 Y  stop
Table 3. Peutz–Jeghers-syndrome-related
complications in 14 patients*
Complications Cases
Anemia 11 (78.6)
Tarry or bloody stool 3 (21.4)
Polyp-related intussusception 9 (64.3)
Polyp-related bowel obstruction 7 (50.0)
Cancer (Colon, lung) 2 (14.3)
Protein-losing enteropathy 1 (7.1)
*Data presented as n (%).
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Patient 5 Patient 4
569 bp
1101 bp
Figure 2. Mutation analysis of the LKB1 cDNA clone in
PJS patients. The heterozygous mutation was detected in
cDNA of case 5 displayed as two fragments of 569 and
1101 bp. The cDNA of case 4 was comparable with the
normal transcript size (1101 bp).
G G A C A
340 350 210 220
T C T G G T C G G C T G G G
C C G G C G G G G C G G C T G G G A A A A G A C C T C C G TC T T
190 200 210 220
C C G G A A C N A G C T G C A A A
C G C C C G CGA A AC T T T
130 140
A
C
B
D
Figure 1. LKB1 germline mutations in familial and sporadic Peutz–Jeghers patients. Mutations are arrowed. As per stan-
dard ABI sequencing analysis format, blue = C, black = G, red = T, and green = A. (A) T715G change in case 1 (forward
sequence), TGG (W) TGG (W) + GGG (G); (B) G923A transition in case 2 (reverse sequence), TGG (W) TGG
(W) + TAG (stop); (C) single C insertion at base 117 in case 5 (reverse sequence), CGC (R)CGCC (mutant); (D)
C180G change in case 11 (reverse sequence), TAC (Y) TAC (Y) + TAG (stop).
for the clinician to recognize this syndrome and
follow up these patients regularly to decrease
and prevent related complications. In our patients,
the mean age at diagnosis was 18.9 years, which
was earlier than in a previous study, which has
suggested that diagnosis is usually made in the
second or third decade of life.7 The earlier diag-
nosis in our patients might have been related to
the more extensive polyps located in the GI tract.
Polyps with small bowel, large bowel and stom-
ach involvement were found in 95%, 76% and
64.4% of our patients, respectively. However,
polyps with small bowel, large bowel and stomach
involvement have been found in 64–96%, 60%
and 24–49%, respectively, in other studies.8–10
The reported symptoms/signs of PJS include
abdominal pain, rectal bleeding, anemia, small in-
testine intussusception, bowel obstruction, and
rectal prolapse.7 Anemia was the most common
complication in our PJS patients (78.6%). Nine
of our patients had intussusception, and 7 of
them (77%) were surgically treated. This surgical
rate was higher than that reported in a Japanese
study in which 47% of patients who had intus-
susception required surgery. This discrepancy
could be because our hospital is a tertiary referral
medical center in Taiwan, where most of the pa-
tients were referred and arrived with more severe
disease.
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To prevent repeat laparotomy, many studies
have used intraoperative endoscopy and endo-
scopic polypectomy to replace enterotomy. Two
of our PJS patients (14%) were complicated with
cancer. A dramatically increased relative and ab-
solute risk of GI and extra-GI cancers has been
documented in patients with PJS.3,11–13 To detect
GI tract malignancy early, most experts recom-
mend colonoscopy at intervals of 2–3 years, 
beginning at age 18 years, and upper GI tract sur-
veillance at intervals of 2–3 years from age 25 years.
Surveillance for pancreatic cancer with endo-
scopic or transabdominal ultrasonography should
begin at 30 years of age. Biennial mammography
beginning at age 20 years is recommended in
women.3
Our genetic analysis of PJS patients revealed
four LKB1 gene mutations (57%) in seven pro-
bands. This mutation rate was comparable to that
in a previous study in which germline LKB1 mu-
tations occurred in 50–75% of PJS patients, by
using genomic DNA or cDNA sequencing as 
a primary screen.5 Most of the germline muta-
tions detected in PJS were frameshift or nonsense
changes that resulted in truncated proteins.
Seventy-five percent of the mutations in this
study led to truncated mutations (stop codons 
at 60, 162 and 308) and were located within the
catalytic (kinase) domain of LKB1 (codons 50–
337), which suggests that the activity of the 
serine/threonine kinase was inhibited.
There were two novel mutations identified 
in our study. The first was discovered in a 19-year-
old girl (diagnosed at age 15 years) with a single
cytosine insertion at base 117 that caused a frame-
shift stop at codon 162 and loss of the kinase
function. The second was a missense change (tryp-
tophan > glycine) at position 239 in a 14-year-old
girl. Exchange of tryptophan (the largest amino
acid) to glycine (the smallest amino acid) has
the potential to alter the quaternary structure of
the expressed protein and lead to functional
change, such as interruption of phosphorylation
and post-translational events that are critical 
for STK11 activity. In addition, this transition was
not detected in 200 unrelated healthy individuals,
thus polymorphism was not favored. However,
the mechanism that underlies the region of this
mutation is unclear and the cause of clinical sig-
nificance needs to be clarified by further study.
Two other mutations have been reported pre-
viously. The nonsense mutation in case 2 (codon
308) has been described by Ylikorkala et al.14
However, the phenotype of these two patients
cannot be compared since no clinical informa-
tion was mentioned in the study. Case 11 had a
thymine to guanine substitution at base 180 that
resulted in a premature stop signal at codon 60
[TAC (Tyr) to TAG (stop)], and developed colon
cancer. This mutation has been reported twice pre-
viously, although whether or not those patients
had cancer was not recorded.5
By evaluating the correlation between muta-
tion status and clinical characteristics, Amos et al
discovered that 27% of the detected pathogenic
mutations in LKB1 were missense mutations.
These patients typically have a later time of onset of
PJS symptoms. Truncation of the encoded STK11
gene leads a significantly earlier age of onset of PJS
symptoms than in patients who have a missense
mutation or no detectable mutation of STK11.15
However, we could not reach a similar conclusion
because we do not yet have enough cases.
In conclusion, intussusception, anemia and
cancer were common clinical problems in our PJS
patients. LKB1 germline mutations were detected
in 57% of Taiwanese PJS patients, which con-
firmed that LKB1 is the major gene responsible
for PJS in the Taiwanese population. Combination
of genetic analysis to achieve early diagnosis of
PJS with a regular screening program to decrease
polyp-related complications and the effects of can-
cer is important in the treatment and follow-up
of these patients.
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